Palatin Technologies, Inc. (PTN) Announces Start of Second Phase I Trial of Its Obesity Compound
Palatin Technologies is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with unmet medical needs and significant commercial potential. Obesity is also a focus of the company. Palatin Technologies reported today that a second Phase I clinical trial of AZD2820 has begun with the dosing of the first patient. The compound is administered under the skin and is a peptide melanocortin receptor partial agonist which is under development for treating obesity. The compound is a clinical candidate selected by European drug firm AstraZeneca (NYSE: AZN) from a collaborative research program with Palatin Technologies. AstraZeneca has…